{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:02:24Z","timestamp":1776772944659,"version":"3.51.2"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103861"],"award-info":[{"award-number":["82103861"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province, China","doi-asserted-by":"publisher","award":["2024JJ5457"],"award-info":[{"award-number":["2024JJ5457"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Changes in serum hepatitis B surface antigen (HBsAg) during treatment are associated with HBsAg loss. However, little is known about the trajectory patterns of HBsAg in early treatment and their relationship to subsequent HBsAg loss.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective study was conducted on 166 treatment-naive children with hepatitis B e antigen (HBeAg)\u2013positive chronic hepatitis B (CHB). Latent class trajectory analysis was used to identify trajectory groups of serum HBsAg. Cox proportional hazards models were used to assess the association between HBsAg trajectory groups and HBsAg loss.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median follow-up time was 20.70 (interquartile range, 12.54\u201334.17) months, and HBsAg loss occurred in 70 (42.17%) of all study participants. Using latent class trajectory analysis, HBeAg-positive patients with CHB were classified into 3 trajectory groups: trajectory 1 (sustained stability, 24.70%), trajectory 2 (slow decline, 38.55%), and trajectory 3 (rapid decline, 36.75%), respectively. The risk of achieving HBsAg loss was higher in both trajectory 2 (hazard ratio, 3.65 [95% confidence interval, 1.70\u20137.83]) and trajectory 3 (7.27 [3.01\u201317.61]), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Serum HBsAg levels during early treatment can be classified into distinct trajectory groups, which may serve as an additional predictive indicator for HBsAg loss in HBeAg-positive children with CHB.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae349","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T07:19:17Z","timestamp":1720250357000},"page":"196-203","source":"Crossref","is-referenced-by-count":1,"title":["Trajectories of Serum Hepatitis B Surface antigen (HBsAg) During Treatment and Association With HBsAg Loss in Children With Hepatitis B e Antigen\u2013Positive Chronic Hepatitis B: A Latent Class Trajectory Analysis"],"prefix":"10.1093","volume":"231","author":[{"given":"Zhenzhen","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Maternal and Child Health, Xiangya School of Public Health, Central South University , Changsha ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingping","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Maternal and Child Health, Xiangya School of Public Health, Central South University , Changsha ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Maternal and Child Health, Xiangya School of Public Health, Central South University , Changsha ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Maternal and Child Health, Xiangya School of Public Health, Central South University , Changsha ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Maternal and Child Health, Xiangya School of Public Health, Central South University , Changsha ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayou","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Maternal and Child Health, Xiangya School of Public Health, Central South University , Changsha ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1713-4120","authenticated-orcid":false,"given":"Songxu","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Maternal and Child Health, Xiangya School of Public Health, Central South University , Changsha ,","place":["China"]},{"name":"NHC Key Laboratory of Birth Defect for Research and Prevention, Hunan Provincial Maternal and Child Health Care Hospital , Hunan ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"2025020417115459400_jiae349-B1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"7","author":"GBD 2019 Hepatitis B Collaborators","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025020417115459400_jiae349-B2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S2468-1253(19)30042-1","article-title":"Hepatitis B virus infection in children and adolescents","volume":"4","author":"Indolfi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025020417115459400_jiae349-B3","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet"},{"key":"2025020417115459400_jiae349-B4","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic hepatitis B virus infection","volume":"392","author":"Seto","year":"2018","journal-title":"Lancet"},{"key":"2025020417115459400_jiae349-B5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1086\/521864","article-title":"Long-term outcome in children with chronic hepatitis B: a 24-year observation period","volume":"45","author":"Iorio","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025020417115459400_jiae349-B6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jpeds.2003.11.022","article-title":"The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection","volume":"144","author":"Wen","year":"2004","journal-title":"J Pediatr"},{"key":"2025020417115459400_jiae349-B7","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children","volume":"336","author":"Chang","year":"1997","journal-title":"N Engl J Med"},{"key":"2025020417115459400_jiae349-B8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.28278","article-title":"Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis","volume":"63","author":"Jonas","year":"2016","journal-title":"Hepatology"},{"key":"2025020417115459400_jiae349-B9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jgh.13459","article-title":"Chronic hepatitis B in children: therapeutic challenges and perspectives","volume":"32","author":"Defresne","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"2025020417115459400_jiae349-B10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J Hepatol"},{"key":"2025020417115459400_jiae349-B11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S2468-1253(18)30384-4","article-title":"The widespread rarity of HBsAg loss in chronic hepatitis B","volume":"4","author":"Wedemeyer","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025020417115459400_jiae349-B12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"2025020417115459400_jiae349-B13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/hep.32231","article-title":"Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohort","volume":"75","author":"Terrault","year":"2022","journal-title":"Hepatology"},{"key":"2025020417115459400_jiae349-B14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S2468-1253(16)30189-3","article-title":"Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial","volume":"2","author":"Bourli\u00e8re","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025020417115459400_jiae349-B15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3343\/alm.2019.39.1.67","article-title":"Performance of hepatitis B core-related antigen versus hepatitis B surface antigen and hepatitis B virus DNA in predicting HBeAg-positive and HBeAg-negative chronic hepatitis","volume":"39","author":"Zhang","year":"2019","journal-title":"Ann Lab Med"},{"key":"2025020417115459400_jiae349-B16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/apt.16149","article-title":"Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)","volume":"53","author":"Lim","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2025020417115459400_jiae349-B17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jvh.12889","article-title":"HBsag and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues","volume":"25","author":"Wang","year":"2018","journal-title":"J Viral Hepat"},{"key":"2025020417115459400_jiae349-B18","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/jvh.13599","article-title":"Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trials","volume":"28","author":"De Ridder","year":"2021","journal-title":"J Viral Hepat"},{"key":"2025020417115459400_jiae349-B19","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.26376","article-title":"Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy","volume":"58","author":"Seto","year":"2013","journal-title":"Hepatology"},{"key":"2025020417115459400_jiae349-B20","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/sim.2659","article-title":"A nonlinear latent class model for joint analysis of multivariate longitudinal data and a binary outcome","volume":"26","author":"Proust-Lima","year":"2007","journal-title":"Stat Med"},{"key":"2025020417115459400_jiae349-B21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10654-016-0131-0","article-title":"Trajectories of body mass index before the diagnosis of cardiovascular disease: a latent class trajectory analysis","volume":"31","author":"Dhana","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"2025020417115459400_jiae349-B22","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1161\/STROKEAHA.118.021117","article-title":"Trajectory groups of 24-hour systolic blood pressure after acute ischemic stroke and recurrent vascular events","volume":"49","author":"Kim","year":"2018","journal-title":"Stroke"},{"key":"2025020417115459400_jiae349-B23","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/jvh.13598","article-title":"Long-term benefits of interferon-\u03b1 therapy in children with HBeAg-positive immune-active chronic hepatitis B","volume":"28","author":"Wang","year":"2021","journal-title":"J Viral Hepat"},{"key":"2025020417115459400_jiae349-B24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2019.06.009","article-title":"Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B","volume":"71","author":"Zhu","year":"2019","journal-title":"J Hepatol"},{"key":"2025020417115459400_jiae349-B25","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/jvh.13720","article-title":"Frequent alanine aminotransferase flares and promising antiviral therapy efficacy during the preschool age: an opportunity to achieve HBsAg loss in children with mother-to-child transmitted hepatitis B","volume":"29","author":"Yao","year":"2022","journal-title":"J Viral Hepat"},{"key":"2025020417115459400_jiae349-B26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J Hepatol"},{"key":"2025020417115459400_jiae349-B27","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/gutjnl-2013-306221","article-title":"HBsAg seroclearance with NUCs: rare but important","volume":"63","author":"Cornberg","year":"2014","journal-title":"Gut"},{"key":"2025020417115459400_jiae349-B28","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/liv.13564","article-title":"Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy","volume":"38","author":"Hsu","year":"2018","journal-title":"Liver Int"},{"key":"2025020417115459400_jiae349-B29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0168-8278(15)30136-7","article-title":"Predictors of clinical response: results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB)","volume":"62","author":"Chan","year":"2015","journal-title":"J Hepatol"},{"key":"2025020417115459400_jiae349-B30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to pegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J Hepatol"},{"key":"2025020417115459400_jiae349-B31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1053\/j.gastro.2019.01.015","article-title":"Hepatitis B surface antigen loss: too little, too late and the challenge for the future","volume":"156","author":"Dusheiko","year":"2019","journal-title":"Gastroenterology"},{"key":"2025020417115459400_jiae349-B32","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/apt.13170","article-title":"Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection","volume":"41","author":"Tseng","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2025020417115459400_jiae349-B33","doi-asserted-by":"crossref","first-page":"1121778","DOI":"10.3389\/fimmu.2023.1121778","article-title":"Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-\u03b1in NAs-suppressed chronic hepatitis B patients","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae349\/58624752\/jiae349.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/1\/196\/58624752\/jiae349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/1\/196\/58624752\/jiae349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T17:14:59Z","timestamp":1738689299000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/1\/196\/7708223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,5]]},"published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae349","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,15]]},"published":{"date-parts":[[2024,7,5]]}}}